The Tisch Cancer Institute at Mount Sinai | Strategic Alliance Partners

Joshua Brody, MD, discusses key follow-up data from the phase 3 ECHELON-1 trial in classical Hodgkin lymphoma.

John O. Mascarenhas, MD, discusses current advancement in the treatment landscape of myelofibrosis.

John Mascarenhas, MD, discusses the shifts from monotherapy to combination therapies in the evolving field of myelofibrosis care.

Shambavi Richard, MD, discussed key studies that continue to shape the SOC in both the transplant-eligible and -ineligible populations, the role of transplant in the space, and unmet needs that remain for older and frail patients.

State of Science Summit- Multiple Myeloma: Chaired by Ajai Chari, MD

John O. Mascarenhas, MD, discusses the investigation of pelabresib in myelofibrosis.

T-cell redirection therapy has shown to be effective in patients unresponsive to initial bispecific antibody treatment.

Several inroads have been made in the realm of gastrointestinal cancers, with novel immunotherapy combinations representing a significant advance spanning several tumor types.

Peter Kozuch, MD, discusses the role of circulating tumor DNA in colorectal cancer.

Joshua Brody, MD, discusses the significance of CAR T-cell therapies being used in earlier treatment lines in patients with diffuse large B-cell lymphoma who relapse within their first year of receiving chemotherapy.

Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.

Study findings could be developed into less-invasive method.

Edward Kim, MD, discusses the future role of Y-90 in patients with unresectable hepatocellular carcinoma.

Institutional Perspectives in Cancer- GI: Chaired by Deirdre Cohen, MD

The bispecific antibody REGN5458 elicited rapid responses that were further characterized by their depth, durability, and low incidence of cytokine release syndrome in patients with relapsed/refractory multiple myeloma.

Daratumumab plus induction/consolidation lenalidomide, bortezomib, and dexamethasone elicited higher minimal residual disease-negativity rates vs the RVd combination alone in patients with transplant-eligible newly diagnosed multiple myeloma, including those in high-risk subgroups.

Matthew Galsky, MD, discusses the design and findings of the phase 3 CheckMate 274 trial in urothelial cancer.

The Canopy Cancer Collective, a national nonprofit organization that strives to fuel better treatments and outcomes for pancreatic cancer patients, has awarded The Tisch Cancer Institute at Mount Sinai a $500,000 grant to support continued innovation in its multidisciplinary treatment of pancreatic cancer.

Mount Sinai researcher Natasha Kyprianou, MBBS, PhD, a leading expert on prostate, bladder, and kidney cancer, has been awarded the Richard D. Williams, MD, Prostate Cancer Research Excellence Award by the Urology Care Foundation, the world’s leading nonprofit urological health foundation and official foundation of the American Urological Association.

Matthew Galsky, MD, discusses the rationale of the phase 3 CheckMate 274 trial in urothelial cancer.